Detection of the new SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in five SARS-CoV-2 rapid antigen tests (RATs), Germany, March 20212021년 3월 독일, 5개의 SARS-CoV-2 RAT(Rapid Antigen Tests)에서 우려되는 B.1.1.7 및 B.1.351의 새로운 SARS-CoV-2 변이체 감지Rapid Communication Published on 2021-04-222022-09-10 Journal: Eurosurveillance [Category] MERS, SARS, 변종, 치료기술, [키워드] Abbott analysed B.1.1.7 B.1.351 cell culture supernatant clinical sample comparable conditions detect detection dilutions DMEM FIVE Germany investigated Laboratory molecular nal von minden new SARS-CoV-2 performance rapid antigen test Rapid antigen test(s) Rapid antigen tests RapiGEN RAT RATs Roche Saliva SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Siemens Surveillance Variant(s) of Concern variants of concern VoC while [DOI] 10.2807/1560-7917.ES.2021.26.16.2100413 PMC 바로가기 [Article Type] Rapid Communication
Head-to-Head Evaluation of Five Automated SARS-CoV-2 Serology Immunoassays in Various Prevalence SettingsArticle Published on 2021-04-102022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] Accuracy Analysis Anti-N anti-S anti-SARS-CoV-2 AUC automated characteristic COVID-19 COVID-19 sera diagnostic DiaSorin displaying electrochemiluminescent immunoassay (ECLIA) Enzyme-linked immunosorbent assay (ELISA) epitope Euroimmun FIVE highest immunoassays negative control Negative predictive value NPV performed population-based cohort Positive predictive value PPV Prevalence Probability reference method ROC Roche S-RBD S1/S2 SARS-CoV-2 screening test selected sensitivity sera serology setting specificity [DOI] 10.3390/jcm10081605 PMC 바로가기 [Article Type] Article
Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patientsSARS-CoV-2 항체 양성 다발성 경화증 환자에서 질병 조절 치료의 안전성Article Published on 2021-04-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단, [키워드] 7-point ordinal scale acute respiratory syndrome addition anti-SARS-CoV-2 Asymptomatic Clinical characteristics complications conducted coronavirus Coronavirus disease 2019 COVID-19 COVID-19 complication COVID-19 severity COVID-19 symptom criteria disease disease severity DMT drug Effect Hospitalization Hypothesis Immune cell Infection inhibit lack maintain mild COVID-19 symptoms Multiple multiple sclerosis Patient patients physician positive raise receiving required Roche Safe Safety SARS CoV-2 SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 IgG SARS-COV-2 infection serology serology testing severe COVID-19 Support symptomatic treated Treatment was performed [DOI] 10.1016/j.msard.2021.102754 PMC 바로가기 [Article Type] Article
Rare SARS-CoV-2 antibody development in cancer patients암 환자에서 희귀 SARS-CoV-2 항체 개발Article Published on 2021-04-012022-09-11 Journal: Seminars in oncology [Category] MERS, SARS, 진단, 치료기술, [키워드] adaptive analyzed antibody antibody concentration assumed bead BGI Cancer cancer patient CAST Course COVID-19 develop Diagnosis doubt extraction humoral Hypothesis Immunity immunoassay individual infected with SARS-CoV-2 knowledge MERS-CoV multiple testing other coronaviruses pandemic Pathogenesis Patient positive provided qPCR Roche RT-qPCR SARS-CoV SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV2 SARS-CoV2 antibody development. SARS-CoV2 infection subsequent understanding Vaccine development were used [DOI] 10.1053/j.seminoncol.2020.12.003 PMC 바로가기 [Article Type] Article
Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassayArticle Published on 2021-04-012023-06-19 Journal: International Journal of Infectious Diseases [Category] MERS, SARS, [키워드] anti-SARS-CoV-2 COVID-19 Roche Serological assay validation verification [DOI] 10.1016/j.ijid.2021.02.024 PMC 바로가기
Diagnostic accuracy of two commercial SARS-CoV-2 antigen-detecting rapid tests at the point of care in community-based testing centers커뮤니티 기반 테스트 센터의 진료 현장에서 두 가지 상용 SARS-CoV-2 항원 검출 빠른 테스트의 진단 정확도Research Article Published on 2021-03-312022-08-13 Journal: PLoS ONE [Category] Biology and Life Sciences, COVID-19, SARS, [키워드] (Abbott 95% CI Abbott Accuracy Ag-RDT Ag-RDTs best Characteristics criteria diagnostic Diagnostic accuracy diagnostic tests diagnostic value enrolled False positive Fever independent individual individuals Laboratory less Lower nasopharyngeal swabs objective PanBio participant Participants Patient performed point of care positive positive RT-PCR presenting Rapid Rapid diagnostic test Rapid test Result Roche RT-PCR SARS-CoV-2 SD Biosensor sensitivity single-center specificity Standard Q Ag-RDT structures Symptom symptom onset symptomatic Test Testing typical symptom typical symptoms was obtained WHO criteria yielding [DOI] 10.1371/journal.pone.0248921 PMC 바로가기 [Article Type] Research Article
Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgGArticle Published on 2021-03-312022-10-29 Journal: Microorganisms [Category] COVID-19, [키워드] Abbott SARS-CoV-2 IgG analyzed anti-SARS-CoV-2 anti-SARS-CoV-2 S1 IgG antibody assays binding convalescent convalescent patient coronavirus correlated COVID-19 COVID-19 pandemic detection diagnostic DiaSorin Elecsy ELISA evaluated highest Humoral response IgG immunoassay investigated LIAISON Live virus negative control neutralization neutralization tests New non-responder nucleocapsid pandemic protection Proteins pseudovirus representing Roche S1 IgG S1/S2 Sample SARS-CoV-2 sensitivity Sensitivity and specificity Serological assay serum sample spike subject tested the antibody response titer [DOI] 10.3390/microorganisms9040733 PMC 바로가기 [Article Type] Article
Clinical performance of Roche cobas 6800, Luminex ARIES, MiRXES Fortitude Kit 2.1, Altona RealStar, and Applied Biosystems TaqPath for SARS‐CoV‐2 detection in nasopharyngeal swabs비인두 면봉에서 SARS-CoV-2 검출을 위한 Roche cobas 6800, Luminex ARIES, MiRXES Fortitude Kit 2.1, Altona RealStar 및 Applied Biosystems TaqPath의 임상 성능Comparative Study Published on 2021-03-302022-09-10 Journal: Journal of medical virology [Category] SARS, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Applied Biosystem best Cepheid clinical clinical laboratory Consensus coronavirus coronavirus disease Coronavirus disease 2019 COVID‐19 detection rate discrepancy FIVE followed by healthy controls hospital Laboratory lowest median molecular diagnostics Nasopharyngeal swab nasopharyngeal swab sample Nasopharyngeal swab samples pandemic respiratory resulting Roche SARS‐CoV‐2 SARS‐CoV‐2 severe acute respiratory syndrome Coronavirus significant difference significant differences specificity Swab TaqPath targets tested the healthy Thermo Fisher Scientific transported [DOI] 10.1002/jmv.26940 PMC 바로가기 [Article Type] Comparative Study
Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort MunichArticle Published on 2021-03-302022-10-30 Journal: International Journal of Environmental Research an [Category] COVID-19, SARS, [키워드] 95% CI 95% confidence interval adjusted Asymptomatic Blood Complete COVID-19 defined disease estimate Factor First wave General population health authorities help Infection infection fatality ratio investigated linear mixed model Loss magnitude Mild Munich not affected Odds ratio Older pandemic PCR-positive Population-based cohort study Prevalence public health measures questionnaire Registered reported risk factor Roche SARS-CoV-2 SARS-CoV-2-specific antibody sense of smell sensitivity Seropositivity Seroprevalence specificity transmission pattern Underreporting [DOI] 10.3390/ijerph18073572 PMC 바로가기 [Article Type] Article
Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021화이자/바이오엔텍 코로나19 백신 1차 또는 2차 접종 후 3주 후 70~80세의 강력한 항체 반응, 영국, 2021년 1월~2월Rapid Communication Published on 2021-03-252022-09-12 Journal: Eurosurveillance [Category] 진단, [키워드] antibody Antibody Response approach collected convalescent sera COVID-19 COVID-19 vaccine COVID-19 vaccines COVID-Vaccine dose evaluate first dose immune response Immunity London Mild-to-moderate naïve individual PCR-confirmed Pfizer/BioNTech produced Roche second dose significantly higher single dose spike Spike protein Support United Kingdom Vaccine [DOI] 10.2807/1560-7917.ES.2021.26.12.2100329 PMC 바로가기 [Article Type] Rapid Communication